Loading...
ARWR logo

Arrowhead Pharmaceuticals, Inc.NasdaqGS:ARWR Stock Report

Market Cap US$9.5b
Share Price
US$68.45
n/a
1Y213.3%
7D2.2%
Portfolio Value
​
View

Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Market Cap: US$9.5b

Arrowhead Pharmaceuticals (ARWR) Stock Overview

Develops medicines for the treatment of intractable diseases in the United States. More details

ARWR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 11.95% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

Volatile share price over the past 3 months compared to the US market


ARWR Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

ARWR logo
Arrowhead Pharmaceuticals

Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships

Key Takeaways Advancing RNAi therapy pipeline and global partnerships boost Arrowhead's growth prospects, competitive position, and access to emerging healthcare markets. Strategic collaborations and favorable regulatory trends support revenue stability, strong margins, and opportunities for long-term earnings and expansion.
View narrative
US$57.67
FV
18.7% overvalued intrinsic discount
-14.61%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
ARWR logo
Arrowhead Pharmaceuticals

Rising Healthcare Costs And Patent Expiry Will Crush RNAi Prospects

Key Takeaways Growth is threatened by stricter reimbursement, increased competition from generics and new gene-editing technologies, and potential regulatory headwinds for novel therapies. Heavy dependence on RNAi drugs, a few key pipeline assets, and external partners heightens risks around revenue stability and long-term profitability.
View narrative
US$17
FV
302.6% overvalued intrinsic discount
-48.59%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ARWR logo
Arrowhead Pharmaceuticals

Advanced RNAi Launches Will Harness Demographic And Health Trends

Key Takeaways Rapid clinical progress, global partnerships, and advanced RNAi platform set the stage for accelerated revenue growth and stronger margins beyond current expectations. Early leadership in high-growth markets and aggressive global expansion enable more diversified, resilient earnings streams with significant long-term upside.
View narrative
US$80
FV
14.4% undervalued intrinsic discount
-3.01%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
View Stock Community

Arrowhead Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Arrowhead Pharmaceuticals
Historical stock prices
Current Share PriceUS$70.09
52 Week HighUS$72.36
52 Week LowUS$9.57
Beta1.29
1 Month Change69.87%
3 Month Change138.24%
1 Year Change213.32%
3 Year Change125.59%
5 Year Change-14.56%
Change since IPO34.79%

Recent News & Updates

Recent updates

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Dec 02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade)

Nov 27

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Oct 07
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Aug 21
Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
User avatar

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

May 14
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 03
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Feb 10

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Arrowhead Pharmaceuticals: Hoping Something Sticks

May 27

Shareholder Returns

ARWRUS BiotechsUS Market
7D2.2%-0.9%-0.6%
1Y213.3%20.5%12.4%

Return vs Industry: ARWR exceeded the US Biotechs industry which returned 20.5% over the past year.

Return vs Market: ARWR exceeded the US Market which returned 12.4% over the past year.

Price Volatility

Is ARWR's price volatile compared to industry and market?
ARWR volatility
ARWR Average Weekly Movement11.0%
Biotechs Industry Average Movement11.3%
Market Average Movement6.5%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.0%

Stable Share Price: ARWR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ARWR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003711Chris Anzalonearrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.

Arrowhead Pharmaceuticals, Inc. Fundamentals Summary

How do Arrowhead Pharmaceuticals's earnings and revenue compare to its market cap?
ARWR fundamental statistics
Market capUS$9.52b
Earnings (TTM)-US$1.63m
Revenue (TTM)US$829.45m
11.5x
P/S Ratio
-5,836x
P/E Ratio

Is ARWR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARWR income statement (TTM)
RevenueUS$829.45m
Cost of RevenueUS$0
Gross ProfitUS$829.45m
Other ExpensesUS$831.08m
Earnings-US$1.63m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin100.00%
Net Profit Margin-0.20%
Debt/Equity Ratio123.6%

How did ARWR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 22:17
End of Day Share Price 2025/12/12 00:00
Earnings2025/09/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
Jason Matthew GerberryBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.